Elizabeth Homans's most recent trade in Lyell Immunopharma Inc was a trade of 1,479,500 Option (right to buy) done . Disclosure was reported to the exchange on March 16, 2022.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lyell Immunopharma Inc | Elizabeth Homans | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Mar 2022 | 1,479,500 | 1,479,500 | - | - | Option (right to buy) |